Search - tctmd.com

Displaying 81 - 100 of 149

Sort: Relevancy | Date

Off Script: A (Not So) Brief History of Aspirin’s Rise and Fall

News Opinion Off Script TCT 2019

Off Script: The TWILIGHT of Aspirin? A Brief History of ASA’s Rise and Fall

Kwan S. Lee

September 29, 2019

News Conference News TCT 2019

Oral Anticoagulation After TAVR Doesn’t Reduce Ischemic Cerebral Lesions: AUREA

Michael O'Riordan

September 28, 2019

Presentation TCT 2019

Is Troponin Elevation After Noncardiac Surgery an Indication to Antithrombotic Treatment?

Presenter: Francesco Franchi

September 27, 2019

Presentation TCT 2019

Reversal Strategies for Warfarin and NOACs: The Essentials

Presenter: Teresa Carman

September 27, 2019

Presentation TCT 2019

When and How to Switch to OAC Alone After PCI?

Presenter: Manesh Patel

September 27, 2019

Presentation TCT 2019

AFib Patients at High Ischemic Risk Post-PCI: Role of Triple Therapy or Potent P2Y12 Inhibition?

Presenter: Dominick Angiolillo

September 27, 2019

Presentation TCT 2019

PCI in Patients Requiring OAC: Which OAC and in Whom?

Presenter: Davide Capodanno

September 27, 2019

Debate: Dual Therapy (OAC+SAPT) Should Be the Default Therapy at Discharge in Most Patients - Con: Beware of Ischemic Complications — Not Ready to Drop DAPT Yet!

Presentation TCT 2019

Con: Beware of Ischemic Complications — Not Ready to Drop DAPT Yet!

Presenter: Robert Byrne

September 27, 2019

Debate: Dual Therapy (OAC+SAPT) Should Be the Default Therapy at Discharge in Most Patients - Pro: Dual Therapy (OAC+SAPT) Should Be the Default Therapy at Discharge in Most Patients

Presentation TCT 2019

Pro: Dual Therapy (OAC+SAPT) Should Be the Default Therapy at Discharge in Most Patients

Presenter: C. Michael Gibson

September 27, 2019

News TCT 2019

TCT 2019 Day One: TWILIGHT and Onyx ONE Kick Things Off

Shelley Wood

September 26, 2019

News Conference News TCT 2019

AUGUSTUS: Apixaban-Based Dual Therapy Best Across Major Subgroups

Todd Neale

September 26, 2019

News Conference News TCT 2019

Onyx ONE: Shorter DAPT Plus ZES Noninferior to Polymer-Free Stent in High-Bleeding-Risk Patients

L.A. McKeown

September 26, 2019

Presentation TCT 2019

Long-Term Antithrombotic Therapy After PCI: How Do I Incorporate COMPASS Into My Practice?

Presenter: Robert Welsh

September 26, 2019

News Conference News TCT 2019

TWILIGHT: Ticagrelor Monotherapy Lowers Bleeding Without Increasing Ischemic Events

Yael L. Maxwell

September 26, 2019

Presentation TCT 2019

Antithrombotic Therapy in PCI Patients With Atrial Fibrillation

Presenter: Marco Valgimigli

September 25, 2019

News Conference News TCT 2018

Statin Preloading Benefit More Pronounced in STEMI Patients: SECURE-PCI

Michael O'Riordan

October 05, 2018

News Conference News TCT 2018

More GLOBAL LEADERS: No Benefit of Ticagrelor Monotherapy in New Analyses

Michael O'Riordan

September 24, 2018

News Conference News TCT 2018

OAC-ALONE: No Clear Answer for Best Therapy Beyond 1 Year After PCI in A-fib Patients

Todd Neale

September 24, 2018

Presentation TCT 2018

US and ESC Guidelines and Consensus on Antithrombotic Therapy in Patients With Atrial Fibrillation Undergoing PCI

Presenter: Davide Capodanno, Giulio Stefanini, Dominick J. Angiolillo

September 23, 2018

Presentation TCT 2018

Utility of Cangrelor During PCI and Bridging Who Benefits Most?

Presenter: John A. Bittl, C. Michael Gibson, Deepak L. Bhatt

September 23, 2018

Advertisement

Off Script: The TWILIGHT of Aspirin? A Brief History of ASA’s Rise and Fall

Oral Anticoagulation After TAVR Doesn’t Reduce Ischemic Cerebral Lesions: AUREA

Is Troponin Elevation After Noncardiac Surgery an Indication to Antithrombotic Treatment?

Reversal Strategies for Warfarin and NOACs: The Essentials

When and How to Switch to OAC Alone After PCI?

AFib Patients at High Ischemic Risk Post-PCI: Role of Triple Therapy or Potent P2Y12 Inhibition?

PCI in Patients Requiring OAC: Which OAC and in Whom?

Con: Beware of Ischemic Complications — Not Ready to Drop DAPT Yet!

Pro: Dual Therapy (OAC+SAPT) Should Be the Default Therapy at Discharge in Most Patients

TCT 2019 Day One: TWILIGHT and Onyx ONE Kick Things Off

AUGUSTUS: Apixaban-Based Dual Therapy Best Across Major Subgroups

Onyx ONE: Shorter DAPT Plus ZES Noninferior to Polymer-Free Stent in High-Bleeding-Risk Patients

Long-Term Antithrombotic Therapy After PCI: How Do I Incorporate COMPASS Into My Practice?

TWILIGHT: Ticagrelor Monotherapy Lowers Bleeding Without Increasing Ischemic Events

Antithrombotic Therapy in PCI Patients With Atrial Fibrillation

Statin Preloading Benefit More Pronounced in STEMI Patients: SECURE-PCI

More GLOBAL LEADERS: No Benefit of Ticagrelor Monotherapy in New Analyses

OAC-ALONE: No Clear Answer for Best Therapy Beyond 1 Year After PCI in A-fib Patients

US and ESC Guidelines and Consensus on Antithrombotic Therapy in Patients With Atrial Fibrillation Undergoing PCI

Utility of Cangrelor During PCI and Bridging Who Benefits Most?

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content